Emergent BioSolutions Inc 2025 SR
The report outlines Emergent BioSolutions' environmental, social, and governance performance for 2025. Key achievements include completing a sustainability compliance roadmap, conducting a climate-related risk assessment, and obtaining limited assurance for its 2024 Scope 1 and Scope 2 greenhouse gas emissions. On the social front, the company celebrated the 10-year anniversary of FDA-approved NARCAN Nasal Spray and expanded access to opioid emergency treatments. Additionally, Emergent achieved a 93% participation rate in its employee engagement surveys and continued to foster a strong culture of quality and compliance.
Company: Emergent BioSolutions Inc
Sector: Manufacturing
Country: United States
Year: 2025
Type: SR
Pages: 45
Back to company
Emergent BioSolutions Inc
ESG Report
The report outlines Emergent BioSolutions' environmental, social, and governance performance for 2025. Key achievements include completing a sustainability compliance roadmap, conducting a climate-related risk assessment, and obtaining limited assurance for its 2024 Scope 1 and Scope 2 greenhouse gas emissions. On the social front, the company celebrated the 10-year anniversary of FDA-approved NARCAN Nasal Spray and expanded access to opioid emergency treatments. Additionally, Emergent achieved a 93% participation rate in its employee engagement surveys and continued to foster a strong culture of quality and compliance.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
2025
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Workplace Fatalities
Employees